Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky weekÂ
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Puma Biotech (PBYI) Tops Q4 EPS by 31c
March 3, 2022 4:21 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.21, $0.31 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $51 million versus the consensus estimate of $46.85 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
... More


